ArticleChest2026
Clinician Views on Inhaler Substitution in the Veterans Health Administration.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn July 2021, the Veterans Health Administration (VHA) implemented a nationwide inhaler formulary change affecting approximately 260,000 veterans with COPD and asthma. Clinician perceptions regarding this formulary change are unknown. RESEARCH QUESTION: What were VHA clinician perspectives on the inhaler formulary change from budesonide-formoterol metered-dose inhaler (MDI) to fluticasone-salmeterol dry-powder inhaler? STUDY DESIGN AND
methodsThis cross-sectional survey study was conducted from September 16, 2024, to October 18, 2024. Respondents completed a 10-item questionnaire assessing their experiences with the formulary change, including structured and open-ended questions. The online survey was distributed via national VHA listservs targeting pulmonologists, pharmacists, and primary care providers and included clinicians practicing during the 2021 inhaler formulary change. Main outcomes were clinician-reported perceptions of veteran notification and education, the presence of local facility implementation champions, and overall sentiment expressed in optional open-ended comments.
resultsAmong 511 respondents who completed the survey, 258 (50.5%) were pharmacists, 157 (30.7%) pulmonologists, 75 (14.7%) primary care providers, 12 (2.3%) other specialties, and 9 (1.8%) did not provide their specialty. Although a slight majority (54.4%) agreed or strongly agreed that veterans were informed of the formulary change in advance, only 24.7% considered the inhaler education provided to be effective. Among 237 open-ended responses, 179 (75.5%) expressed a negative sentiment about the formulary change, 28 (11.8%) were neutral, 8 (3.4%) were positive, and 22 (9.3%) gave insufficient detail for grading. Themes included poor inhaler tolerance, concerns about worsening patient outcomes, and increased provider workload. Pulmonologists displayed lower awareness than pharmacists and primary care providers regarding the methods used to inform and educate veterans about the formulary change.
interpretationVHA clinicians reported predominantly negative perceptions of the 2021 inhaler formulary change, underscoring the importance of timely clinician communication, patient education, and specialty engagement in future formulary transitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.